Klaria Pharma Holding AB (publ.) (FRA:6FN)
Germany · Delayed Price · Currency is EUR 0.0406
-0.0042 (-9.38%)
At close: Nov 28, 2025
Klaria Pharma Holding AB (publ.) Company Description
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock.
Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection.
The company is also involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquartered in Uppsala, Sweden.
Klaria Pharma Holding AB (publ.)
| Country | Sweden |
| Founded | 2014 |
| Industry | Pharmaceutical Preparations |
| Employees | 4 |
| CEO | Scott Boyer |
Contact Details
Address: Virdings Allé 2 Uppsala, 754 50 Sweden | |
| Phone | 46 84 46 42 99 |
| Website | klaria.com |
Stock Details
| Ticker Symbol | 6FN |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Scott Boyer | Chief Executive Officer |
| Hans Richter | Chief Financial Officer |